$IMAQ
International Media Acquisition Corp. Stock $imaq

$imaq Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000165495423009151 Filed on July 14, 2023

Income Statement

Concept	2023 Q1	2023	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$363.9K	$2.236M	$458.7K
YoY Change	-20.67%	387.5%	29879.08%
Operating Profit		-$2.236M	-$458.7K
YoY Change			29977.05%
Interest Expense	$226.6K	$1.208M	$142.7K
YoY Change	58.77%	746.74%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$137.3K	-$1.028M	-$316.0K
YoY Change	-56.54%	225.27%	20552.29%
Income Tax	$49.98K	$207.6K	$0.00
% Of Pretax Income
Net Earnings	-$187.3K	-$1.235M	-$316.0K
YoY Change	-40.73%	290.98%	20619.93%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.08	-$0.01
Diluted Earnings Per Share	-$0.02	-$0.15	-$0.01
COMMON SHARES
Basic Shares Outstanding	8.520M	15.29M shares	29.55M
Diluted Shares Outstanding		15.29M shares	29.55M

Balance Sheet

Concept	2023 Q1	2023	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$300.00	$300.00	$107.7K
YoY Change	-99.72%	-99.72%	1442.69%
Cash & Equivalents	$302.00		$107.7K
Short-Term Investments
Other Short-Term Assets	$52.50K	$52.50K	$192.2K
YoY Change	-72.68%	-72.68%
Inventory
Prepaid Expenses	$52.50K		$192.2K
Receivables
Other Receivables
Total Short-Term Assets	$52.80K	$52.80K	$299.9K
YoY Change	-82.39%	-82.39%	4196.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$20.98M	$20.98M	$230.0M
YoY Change	-90.88%	-90.88%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$20.98M	$20.98M	$230.0M
YoY Change	-90.88%	-90.88%	65273.56%
TOTAL ASSETS
Total Short-Term Assets	$52.80K	$52.80K	$299.9K
Total Long-Term Assets	$20.98M	$20.98M	$230.0M
Total Assets	$21.03M	$21.03M	$230.3M
YoY Change	-90.87%	-90.87%	64085.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.193M	$1.193M	$494.0K
YoY Change	141.45%	141.45%
Accrued Expenses	$200.0K	$200.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$2.126M	$2.126M	$195.0K
YoY Change	990.02%	990.02%	-34.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.726M	$3.726M	$689.0K
YoY Change	440.78%	440.78%	105.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.074M	$8.074M	$8.193M
YoY Change	-1.46%	-1.46%
Total Long-Term Liabilities	$8.074M	$8.074M	$8.193M
YoY Change	-1.46%	-1.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.726M	$3.726M	$689.0K
Total Long-Term Liabilities	$8.074M	$8.074M	$8.193M
Total Liabilities	$11.80M	$11.80M	$8.882M
YoY Change	32.84%	32.84%	2548.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.05M		-$9.118M
YoY Change	21.23%
Common Stock	$655.00		$655.00
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.231M	$9.231M	-$8.553M
YoY Change
Total Liabilities & Shareholders Equity	$21.03M	$21.03M	$230.3M
YoY Change	-90.87%	-90.87%	64085.54%

Cashflow Statement

Concept	2023 Q1	2023	2022 Q1
OPERATING ACTIVITIES
Net Income	-$187.3K	-$1.235M	-$316.0K
YoY Change	-40.73%	290.98%	20619.93%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.198M	-$1.198M	-$312.0K
YoY Change	283.83%	283.84%	59332.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$210.1M	$210.1M
YoY Change
Cash From Investing Activities	$210.1M	$210.1M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$211.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-209.0M	-209.0M	195.0K
YoY Change	-107305.12%	-107305.12%	2500.0%
NET CHANGE
Cash From Operating Activities	-1.198M	-1.198M	-312.0K
Cash From Investing Activities	210.1M	210.1M	$0.00
Cash From Financing Activities	-209.0M	-209.0M	195.0K
Net Change In Cash	-107.4K	-107.4K	-117.0K
YoY Change	-8.24%	-8.24%	-1777.75%
FREE CASH FLOW
Cash From Operating Activities	-$1.198M	-$1.198M	-$312.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001846235
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q1	imaq	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1	integer
CY2023Q1	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	385541	usd
CY2022Q3	imaq	Number Of Times Combination Period Can Be Extended NumberOfTimesCombinationPeriodCanBeExtended	2	integer
CY2023	imaq	Threshold Business Days For Redemption Of Public Shares ThresholdBusinessDaysForRedemptionOfPublicShares	P10D
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107684	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1351448	usd
CY2023Q1	imaq	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	2	integer
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6546900	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6546900	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6546900	shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40687
CY2023	dei	Entity Registrant Name EntityRegistrantName	INTERNATIONAL MEDIA ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1627460
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1604 US Highway 130
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	North Brunswick
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08902
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	960-3677
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2022Q3	dei	Entity Public Float EntityPublicFloat	88191269	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8520018	shares
CY2023	dei	Auditor Firm AuditorFirmId	3223
CY2023	dei	Auditor Name AuditorName	Mercurius & Associates LLP
CY2023	dei	Auditor Location AuditorLocation	New Delhi, India
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	302	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107684	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	224707	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	52500	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	192200	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	238953	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	52802	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	299884	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	463660	usd
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	20978456	usd
CY2022Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	230029939	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	230006777	usd
CY2023Q1	us-gaap	Assets Assets	21031258	usd
CY2022Q1	us-gaap	Assets Assets	230329823	usd
CY2021Q4	us-gaap	Assets Assets	230470437	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1192707	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	413979	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	394079	usd
CY2023Q1	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	200000	usd
CY2022Q1	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	80000	usd
CY2021Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	0	usd
CY2023Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2125541	usd
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	195000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	207632	usd
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3725880	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	688979	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	394079	usd
CY2023Q1	imaq	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000	usd
CY2022Q1	imaq	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000	usd
CY2021Q4	imaq	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000	usd
CY2023Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	23907	usd
CY2022Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	143442	usd
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	262977	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11799787	usd
CY2022Q1	us-gaap	Liabilities Liabilities	8882421	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8707056	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	20284026	usd
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	230000000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	230000000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	655	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	655	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	655	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	564600	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	564600	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11053210	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9117853	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8801874	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11052555	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8552598	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-8236619	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21031258	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230329823	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230470437	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2236077	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	458675	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	736960	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1351448	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2236077	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-458675	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2088408	usd
CY2023	imaq	Offering Cost Incurred OfferingCostIncurred	0	usd
CY2022Q1	imaq	Offering Cost Incurred OfferingCostIncurred	0	usd
	imaq	Offering Cost Incurred OfferingCostIncurred	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	119535	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	119535	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	199225	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1088765	usd
CY2022Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	23161	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6777	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1027777	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-315979	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1882406	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207632	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1235409	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-315979	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1882406	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15291778	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29546900	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15189291	shares
CY2023	imaq	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.08
CY2022Q1	imaq	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.01
	imaq	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.12
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	0	usd
	imaq	Issuance Of Common Stock To Sponsor Amount IssuanceOfCommonStockToSponsorAmount	25000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11644529	usd
	imaq	Stock Issued During Period Value Public Rights StockIssuedDuringPeriodValuePublicRights	6853620	usd
	imaq	Proceeds From Sale Of Private Units To Sponsor Allocated To Private Shares Net Of Offering Costs Amount ProceedsFromSaleOfPrivateUnitsToSponsorAllocatedToPrivateSharesNetOfOfferingCostsAmount	7174000	usd
	imaq	Stock Issued During Period Value Private Units To Sponsor Allocated To Private Rights StockIssuedDuringPeriodValuePrivateUnitsToSponsorAllocatedToPrivateRights	250879	usd
	imaq	Accretion Of Public Share To Redemption Value AccretionOfPublicShareToRedemptionValue	-33653689	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1351448	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1882406	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-8236619	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-315979	usd
CY2022Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8552598	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1235409	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-1264548	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11052555	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-1235409	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-315979	usd
	us-gaap	Profit Loss ProfitLoss	-1882406	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1351448	usd
CY2023	imaq	Offering Costs Incurred OfferingCostsIncurred	0	usd
CY2022Q1	imaq	Offering Costs Incurred OfferingCostsIncurred	0	usd
	imaq	Offering Costs Incurred OfferingCostsIncurred	4926	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1088765	usd
CY2022Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	23161	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6777	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	119535	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	119535	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	199225	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	139700	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	46752	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-238953	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	898728	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	99900	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	394079	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	207632	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1197649	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-312023	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-576908	usd
CY2023	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	-1085541	usd
CY2022Q1	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	0	usd
	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	-230000000	usd
CY2023	imaq	Proceeds From Trust Account To Pay Taxes ProceedsFromTrustAccountToPayTaxes	245266	usd
CY2022Q1	imaq	Proceeds From Trust Account To Pay Taxes ProceedsFromTrustAccountToPayTaxes	0	usd
	imaq	Proceeds From Trust Account To Pay Taxes ProceedsFromTrustAccountToPayTaxes	0	usd
CY2023	imaq	Proceeds From Trust Account In Connection With Redemption ProceedsFromTrustAccountInConnectionWithRedemption	210980523	usd
CY2022Q1	imaq	Proceeds From Trust Account In Connection With Redemption ProceedsFromTrustAccountInConnectionWithRedemption	0	usd
	imaq	Proceeds From Trust Account In Connection With Redemption ProceedsFromTrustAccountInConnectionWithRedemption	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	210140248	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-230000000	usd
CY2023	imaq	Net Proceeds From Initial Public Offering NetProceedsFromInitialPublicOffering	0	usd
CY2022Q1	imaq	Net Proceeds From Initial Public Offering NetProceedsFromInitialPublicOffering	0	usd
	imaq	Net Proceeds From Initial Public Offering NetProceedsFromInitialPublicOffering	225400000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7240463	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1930541	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	195000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	315000	usd
CY2023	imaq	Advance From Sponsor AdvanceFromSponsor	0	usd
CY2022Q1	imaq	Advance From Sponsor AdvanceFromSponsor	0	usd
	imaq	Advance From Sponsor AdvanceFromSponsor	94537	usd
CY2023	imaq	Repayment Of Advance From Sponsor RepaymentOfAdvanceFromSponsor	0	usd
CY2022Q1	imaq	Repayment Of Advance From Sponsor RepaymentOfAdvanceFromSponsor	0	usd
	imaq	Repayment Of Advance From Sponsor RepaymentOfAdvanceFromSponsor	-94537	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2153848	usd
CY2023	imaq	Payments For Redemption Of Common Stock PaymentsForRedemptionOfCommonStock	-210980522	usd
CY2022Q1	imaq	Payments For Redemption Of Common Stock PaymentsForRedemptionOfCommonStock	0	usd
	imaq	Payments For Redemption Of Common Stock PaymentsForRedemptionOfCommonStock	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-209049981	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	195000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	230801615	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-107382	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-117023	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	224707	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107684	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	224707	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	302	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107684	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	224707	usd
CY2023	imaq	Accretion Of Public Shares To Redemption Value AccretionOfPublicSharesToRedemptionValue	1264548	usd
CY2022Q1	imaq	Accretion Of Public Shares To Redemption Value AccretionOfPublicSharesToRedemptionValue	0	usd
	imaq	Accretion Of Public Shares To Redemption Value AccretionOfPublicSharesToRedemptionValue	33653689	usd
CY2023	imaq	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	0	usd
CY2022Q1	imaq	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	0	usd
	imaq	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	8050000	usd
CY2023	imaq	Repayment Of Promissory Note Through Issuance Of Private Units RepaymentOfPromissoryNoteThroughIssuanceOfPrivateUnits	0	usd
CY2022Q1	imaq	Repayment Of Promissory Note Through Issuance Of Private Units RepaymentOfPromissoryNoteThroughIssuanceOfPrivateUnits	0	usd
	imaq	Repayment Of Promissory Note Through Issuance Of Private Units RepaymentOfPromissoryNoteThroughIssuanceOfPrivateUnits	503537	usd
CY2023	imaq	Offering Costs Paid In Exchange For Private Units OfferingCostsPaidInExchangeForPrivateUnits	0	usd
CY2022Q1	imaq	Offering Costs Paid In Exchange For Private Units OfferingCostsPaidInExchangeForPrivateUnits	0	usd
	imaq	Offering Costs Paid In Exchange For Private Units OfferingCostsPaidInExchangeForPrivateUnits	225000	usd
CY2023	imaq	Deferred Offering Costs Included In Promissory Notes Related Party DeferredOfferingCostsIncludedInPromissoryNotesRelatedParty	0	usd
CY2022Q1	imaq	Deferred Offering Costs Included In Promissory Notes Related Party DeferredOfferingCostsIncludedInPromissoryNotesRelatedParty	0	usd
	imaq	Deferred Offering Costs Included In Promissory Notes Related Party DeferredOfferingCostsIncludedInPromissoryNotesRelatedParty	213537	usd
CY2023	imaq	Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock OfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock	0	usd
CY2022Q1	imaq	Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock OfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock	0	usd
	imaq	Offering Costs Paid By Sponsor In Exchange For Issuance Of Common Stock OfferingCostsPaidBySponsorInExchangeForIssuanceOfCommonStock	25000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">International Media Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on January 15, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is not limited to a particular industry or geographic region (excluding China) for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of March 31, 2023, the Company had not commenced any operations. All activity for the period from January 15, 2021 (inception) through March 31, 2023, related to the Company’s formation and initial public offering (“Initial Public Offering”), which is described below, and identifying a target Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest and dividend income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. On August 16, 2022, the board of directors of International Media Acquisition Corp. (the “<span style="text-decoration:underline">Company</span>”) approved a change to the Company’s fiscal year end from December 31 to March 31, in accordance with the Company’s Bylaws.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As previously disclosed, the Company changed its fiscal year end from December 31 to March 31, effective for the fiscal year beginning April 1, 2022. The Company's current fiscal year began on April 1, 2022 and ended on March 31, 2023 ("Fiscal 2023"). This Annual Report on Form 10-K refers to the period beginning on January 1, 2022 and ending March 31, 2022 as the "transition period". The Company filed a Transition Report on Form 10-QT that included financial information for the Transition Period with the SEC on September 29, 2022. The Company's 2021 fiscal year began on January 1, 2021 and ended on December 31, 2021 ("Fiscal 2021"). There was no Fiscal 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The registration statement filed in connection with the Company’s Initial Public Offering was declared effective on July 28, 2021. On August 2, 2021, the Company consummated the Initial Public Offering of 20,000,000 units (the “Units”), at $10.00 per Unit, generating gross proceeds of $200,000,000, which is discussed in Note 3.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 714,400 units (the “Private Units”), at a price of $10.00 per Private Unit in a private placement to the Company’s sponsor, Content Creation Media LLC (the “Sponsor”), generating gross proceeds of $7,144,000, which is described in Note 4.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 6, 2021, in connection with the underwriters’ exercise in full of their option to purchase up to 3,000,000 additional Units to cover over-allotments, if any, the Company consummated the sale of an additional 3,000,000 Units, generating gross proceeds of $30,000,000.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Simultaneously with the closing of the exercise of the over-allotment option, the Company consummated the sale of an additional 82,500 Private Units, at a price of$10.00 per Private Unit, in a private placement to the Sponsor, generating gross proceeds of $825,000.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Following the closing of the Initial Public Offering and the sale of the Private Units, a total of$230,000,000 was placed in a trust account (the “Trust Account”) and was invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company will provide the holders (the “public stockholders”) of the shares of common stock included in the Units sold in the Initial Public Offering (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s rights or warrants. The Public Shares subject to redemption are recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 Distinguishing Liabilities from Equity(“ASC 480”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either prior to or upon such consummation of a Business Combination and, if the Company seeks stockholder approval and assuming a quorum is present at the meeting, the affirmative vote of a majority of the shares of common stock present in person or represented by proxy and entitled to vote at the meeting are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and the other holders of the Founder Shares (as defined in Note 5) have agreed to vote their Founder Shares, their Private Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or don’t vote at all.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Notwithstanding the above, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Sponsor and the other initial stockholders (as defined in Note 5) have agreed (a) to waive their redemption rights with respect to their Founder Shares, Private Shares and Public Shares held by them in connection with the completion of a Business Combination, (b) to waive their liquidation rights with respect to their Founder Shares and Private Shares if the Company fails to complete (a Business Combination within 15 months (or up to 18 months if the Company extends the period of time) from the closing of the Initial Public Offering and (c) not to propose an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 15 months (or up to 18 months if the Company extends the period of time) from the closing of the Initial Public Offering, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. However, if the Sponsor and the other initial stockholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period (as defined below).</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company will have until 15 months (or up to 18 months if the Company extends the period of time) from the closing of the Initial Public Offering to complete a Business Combination (the “Combination Period”). On January 27, 2023, IMAQ held a special meeting of stockholders (the “Special Meeting”). As approved by its stockholders at the Special Meeting, the Company filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) which became effective upon filing. The Charter Amendment changed the date by which IMAQ must consummate an initial business combination for an additional three (3) months, from February 2, 2023 to May 2, 2023, with an ability to further extend by three (3) additional one (1) month periods until August 2, 2023 (the “Amended Combination Period”). If the Company is unable to complete a Business Combination within the Amended Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding Public Shares for a pro rata portion of the funds held in the Trust Account, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining holders of common stock and the board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s rights and warrants, which will expire worthless if the Company fails to complete a Business Combination within the Amended Combination Period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The underwriters have agreed to waive their rights to their deferred underwriting commissions (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Amended Combination Period, and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third-party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On October 22, 2022, International Media Acquisition Corp. (“IMAQ”) entered into a Stock Purchase Agreement (the “SPA”) with Risee Entertainment Holdings Private Limited, a company incorporated in India (“Seller”), and Reliance Entertainment Studios Private Limited, company incorporated in India (the “Target Company”). Pursuant to the terms of the SPA, a business combination between the Company and the Target Company will be effected by the acquisition of 100% of the issued and outstanding share capital of the Target Company from Seller in a series of transactions (collectively, the “Stock Acquisition”). The aggregate purchase price for the shares of the Target Company under the SPA is $102,000,000, and in addition, the Company also agreed to make a primary investment into the Target Company in the amount of $38,000,000, which will be used solely for the purposes of repayment of inter-company loans aggregating to $38,000,000 as existing on the books of the Target Company at the initial closing of the Stock Acquisition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Extension Payment and Shares Redemption</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Initially, the Company was required to complete its initial business combination transaction by August 2, 2022, which was 12 months from the closing of the Initial Public Offering (the “Combination Period”). On July 26, 2022, at a special meeting of the Company’s stockholders (the “Extension Meeting”), the stockholders approved a proposal to amend the Company’s investment management trust agreement, dated as of July 28, 2021 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), allowing the Company to extend the Combination Period two times for an additional three months each time, or from August 2, 2022 to February 2, 2023 (the “Trust Amendment”) by depositing into the Trust Account $350,000 for each three-month extension. In connection with the proposal, the Company’s public stockholders had the right to redeem their shares of common stock for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. Public stockholders holding 21,026,882 shares of the Company’s common stock (out of a total of 23,000,000 shares of common stock held by public stockholders) exercised their right to redeem such shares at a redemption price of approximately $10.03 per share. On January 27, 2023, IMAQ held a special meeting of stockholders (the “Special Meeting”). As approved by its stockholders at the Special Meeting, the Company filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) which became effective upon filing. The Charter Amendment changed the date by which IMAQ must consummate an initial business combination for an additional three (3) months, from February 2, 2023 to May 2, 2023, with an ability to further extend by three (3) additional one (1) month periods until August 2, 2023 (the “Amended Combination Period”).</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On July 26, 2022, the extension payment of $350,000 was deposited by the Sponsor into the Company’s Trust Account to extend the August 2, 2022, deadline to November 2, 2022.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On October 28, 2022, a second extension payment of $350,000 was deposited by the Sponsor into the Company’s Trust Account to extend the November 2, 2022, deadline to February 2, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On February 3, 2023, third extension payment of $385,541 was deposited by the Sponsor into the Company’s Trust Account to extend the February 2, 2023, deadline to May 2, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On June 1, 2023, a fourth partial extension payment of $128,513 was deposited by the Sponsor into the Company’s Trust Account to extend the May 2, 2023, deadline to August 2, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On June 23, 2023, fifth partial extension payment of $128,513 was deposited by the Sponsor into the Company’s Trust Account to extend the May 2, 2023, deadline to August 2, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On July 11, 2023, the sixth complete extension payment of $128,513 was deposited by the Sponsor into the Company’s Trust Account to extend the May 2, 2023, deadline to August 2, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Liquidity and Going Concern</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of March 31, 2023, the Company held cash outside the Trust Account of $302 available for working capital needs. All remaining cash held in the Trust Account is generally unavailable for the Company’s use, prior to an initial Business Combination, and is restricted for use either in a Business Combination, to redeem Common Stock or for making tax payments.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has until February 2, 2023, to consummate a Business Combination. The Company elected to take second extension, Sponsor deposited into the Trust Account $350,000 to extend the deadline from November 2, 2022, to February 2, 2023.On January 27, 2023, IMAQ held a special meeting of stockholders (the “Special Meeting”). As approved by its stockholders at the Special Meeting, the Company filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) which became effective upon filing. The Charter Amendment changed the date by which IMAQ must consummate an initial business combination for an additional three (3) months, from February 2, 2023 to May 2, 2023, with an ability to further extend by three (3) additional one (1) month periods until August 2, 2023 (the “Amended Combination Period”). On February 3, 2023, third extension payment of $385,541 was deposited by the Sponsor into the Company’s Trust Account to extend the February 2, 2023, deadline to May 2, 2023 and between June and July 2023 further three extension payment amounting to $385,539 was deposited by the Sponsor into the Company’s Trust Account to extend the May 2, 2023, deadline to August 2, 2023</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a Business Combination is not consummated by August 2, 2023, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the mandatory liquidation, if a Business Combination does not occur, raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after August 2, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination by August 2, 2023, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after August 2, 2023. Management plans to continue to draw down the funds on its promissory notes, repayable only if there is a Business Combination. The Company intends to complete a Business Combination before the mandatory liquidation date.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Risks and Uncertainties</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a prospective target company, the specific impact is not readily determinable as of the date of these financial statements.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Additionally, as a result of the military action commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	230000000	usd
CY2021Q3	imaq	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001	usd
CY2023	imaq	Redemption Limit Percentage Without Prior Consent RedemptionLimitPercentageWithoutPriorConsent	20	pure
CY2023	imaq	Months To Complete Acquisition MonthsToCompleteAcquisition	P15Y
CY2023	imaq	Maximum Extended Months To Complete Acquisition MaximumExtendedMonthsToCompleteAcquisition	P18M
CY2023	imaq	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2022Q3	imaq	Extension Period For Combination ExtensionPeriodForCombination	P3M
CY2022Q3	imaq	Months To Complete Acquisition MonthsToCompleteAcquisition	P12Y
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	21026882	shares
CY2022Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	23000000	shares
CY2022Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.03
CY2022Q3	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	350000	usd
CY2022Q4	imaq	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	350000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.</p>
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	17847675	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1235409	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2198385	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1882406	usd
CY2023	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15291778	shares
CY2022	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21165679	shares
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15189291	shares
CY2023	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2022	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2023	us-gaap	Concentration Risk Credit Risk Financial Instrument Maximum Exposure ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure	250000	usd
CY2023	imaq	Underwriting Cash Discount Per Unit UnderwritingCashDiscountPerUnit	0.20
CY2023	imaq	Underwriter Cash Discount UnderwriterCashDiscount	4600000	usd
CY2023Q1	imaq	Deferred Fee Per Unit DeferredFeePerUnit	0.35
CY2023Q1	imaq	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	8050000	usd
CY2023	imaq	Period For Right Of First Refusal To Act As Book Running Manager After Date Of Consummation Of Business Combination PeriodForRightOfFirstRefusalToActAsBookRunningManagerAfterDateOfConsummationOfBusinessCombination	P18M
CY2023	imaq	Percentage Of Economics For Future Public And Private Equity And Debt Offerings PercentageOfEconomicsForFuturePublicAndPrivateEquityAndDebtOfferings	0.30	pure
CY2021Q1	imaq	Agreed To Pay Maximum Amount Subject To Successfully Completing Business Combination AgreedToPayMaximumAmountSubjectToSuccessfullyCompletingBusinessCombination	400000	usd
CY2021Q1	imaq	Agreed To Pay Uncomplete Business Combination Within Combination Period AgreedToPayUncompleteBusinessCombinationWithinCombinationPeriod	40000	usd
CY2023	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	10000	usd
CY2023Q1	us-gaap	Assets Under Management Carrying Amount AssetsUnderManagementCarryingAmount	40000	usd
CY2023	imaq	Percentage Of Fee Based On Target Introduced In Business Combination PercentageOfFeeBasedOnTargetIntroducedInBusinessCombination	0.005	pure
CY2023	imaq	Reimbursement Of Out Of Pocket Expenses ReimbursementOfOutOfPocketExpenses	25000	usd
CY2023	imaq	Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination	P30D
CY2023Q1	imaq	Number Of Warrants Issued NumberOfWarrantsIssued	23796900	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6546900	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1973118	shares
CY2023	imaq	Class Of Warrant Or Right Number Of Rights In Multiples Required To Receive Shares ClassOfWarrantOrRightNumberOfRightsInMultiplesRequiredToReceiveShares	20	shares
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	20978456	usd
	imaq	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Beginning FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueBeginning	0	usd
	imaq	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Initial Measurement FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInitialMeasurement	414352	usd
	imaq	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueEnding	462202	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-199225	usd
	imaq	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueEnding	262977	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-119535	usd
CY2022Q1	imaq	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueEnding	143442	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-119535	usd
CY2023	imaq	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueEnding	23907	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	119535	usd
CY2023Q1	imaq	Deferred Tax Asset Start Up Costs DeferredTaxAssetStartUpCosts	165204	usd
CY2022Q1	imaq	Deferred Tax Asset Start Up Costs DeferredTaxAssetStartUpCosts	272333	usd
CY2021Q4	imaq	Deferred Tax Asset Start Up Costs DeferredTaxAssetStartUpCosts	165204	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	34242	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	40934	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	34242	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	199446	usd
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	313268	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	199446	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	199446	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	313268	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	199446	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	141155	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	66478	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-396050	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-243762	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-152304	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-134091	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-69505	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-47412	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	530142	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	313268	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	199446	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	207632	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	216874	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023Q1	imaq	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiability	0.0327	pure
CY2022Q1	imaq	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiability	0.0391	pure
CY2021Q4	imaq	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiability	0.0291	pure
CY2023Q1	imaq	Effective Income Tax Rate Reconciliation Expensed Offering Costs EffectiveIncomeTaxRateReconciliationExpensedOfferingCosts	0	pure
CY2022Q1	imaq	Effective Income Tax Rate Reconciliation Expensed Offering Costs EffectiveIncomeTaxRateReconciliationExpensedOfferingCosts	-0.0006	pure
CY2021Q4	imaq	Effective Income Tax Rate Reconciliation Expensed Offering Costs EffectiveIncomeTaxRateReconciliationExpensedOfferingCosts	-0.0007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.5158	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1425	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1060	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.1659	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.1974	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	-0.2020	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0	pure

Files In Submission

Name	View Source	Status
0001654954-23-009151-index-headers.html	Edgar Link	pending
0001654954-23-009151-index.html	Edgar Link	pending
0001654954-23-009151.txt	Edgar Link	pending
0001654954-23-009151-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
imac_10k.htm	Edgar Link	pending
imac_ex311.htm	Edgar Link	pending
imac_ex312.htm	Edgar Link	pending
imac_ex321.htm	Edgar Link	pending
imac_ex322.htm	Edgar Link	pending
imaq-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imaq-20230331_cal.xml	Edgar Link	unprocessable
imaq-20230331_def.xml	Edgar Link	unprocessable
imaq-20230331_lab.xml	Edgar Link	unprocessable
imac_10k_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
imaq-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMAQ
International Media Acquisition Corp. Stock $imaq

2023 Q1 Form 10-K Financial Statement

#000165495423009151 Filed on July 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMAQ International Media Acquisition Corp. Stock $imaq

2023 Q1 Form 10-K Financial Statement

#000165495423009151 Filed on July 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMAQ
International Media Acquisition Corp. Stock $imaq